Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16016392 | 0.82 | MPO (0.40) | MPOCXCR2AKR1B1CD38P2RX7 | |
| SCHEMBL16018768 | 0.76 | SLC6A3 (0.40) | MPOCXCR2HTR1BCX3CR1GRM4 | |
| SCHEMBL19220559 | 0.75 | MPO (0.37) | MPOCXCR2HTR1BCX3CR1AKR1B1 | |
| SCHEMBL16018765 | 0.74 | MPO (0.36) | MPOCXCR2HTR1BCX3CR1AKR1B1 | |
| SCHEMBL16018767 | 0.73 | POLB (0.45) | MPOCXCR2HTR1BCX3CR1 | |
| SCHEMBL16018757 | 0.72 | PTGS2 (0.37) | MPOGRM4 | |
| SCHEMBL16018751 | 0.71 | HTR6 (0.38) | HTR6 | |
| SCHEMBL16018773 | 0.68 | MPO (0.40) | MPOCXCR2HTR1BCX3CR1AKR1B1 | |
| SCHEMBL16018770 | 0.68 | SLC5A2 (0.46) | MPOCXCR2HTR1BCX3CR1P2RX7 | |
| SCHEMBL16018764 | 0.67 | MPO (0.36) | MPOCXCR2AKR1B1CFDP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200009-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | MPO 4689/4885CXCR2 4615/4885HTR1B 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.